Comparison of tocilizumab and intravenous immunoglobulin treatment in intensive care unit patients with COVID-19 who developed cytokine storm: A single-center retrospective study

Basit Öğe Kaydı
dc.contributor.authorKalkan, Serkan
dc.contributor.authorDemircan, Selcuk
dc.contributor.authorDisli, Zeliha Korkmaz
dc.contributor.authorDuzenci, Deccane
dc.contributor.authorMemisoglu, Funda
dc.contributor.authorYalcinsoy, Murat
dc.contributor.authorBicakcioglu, Murat
dc.date.accessioned2026-04-04T13:30:49Z
dc.date.available2026-04-04T13:30:49Z
dc.date.issued2024
dc.departmentİnönü Üniversitesi
dc.description.abstractAim: Coronavirus disease 2019 (COVID-19) may trigger a severe inflammatory response. In the present study, the effects of tocilizumab and intravenous immunoglobulin (IVIG) on mortality in COVID-19 patients with cytokine storms were examined and compared. Material and Methods: This retrospective study included all COVID-19 patients who were diagnosed and followed in the intensive care unit between April 2020 and May 2022. The patients were divided into two groups depending on whether they were receiving IVIG or tocilizumab treatment. In addition to the patients' demographic information, the 28-day mortality was recorded. Their PaO2/FiO2 ratio, CRP, procalcitonin, lymphocyte, ferritin, and D-dimer levels were also recorded before drug administration and on the first day, third day, and first week following the drug administration. Results: Of the 73 patients included in this study, 43 (59%) received tocilizumab (Group T), while 30 (41%) received IVIG treatment (Group IVIG). No significant statistical differences were detected between the groups in terms of demographic data, pre-drug inflammatory parameters, improvement in PaO2/FiO2 ratios, and 28-day mortality. The rate of change in CRP levels was significantly higher in Group T than in Group IVIG on day 3 (p=0.010) and in the first week (p=0.001). The improvement in ferritin levels in the first week was significantly higher in Group T (p=0.018). Discussion: No significant difference was detected between the effects of IVIG and tocilizumab on mortality in COVID-19 patients with cytokine storm. However, tocilizumab suppressed inflammation more strongly than IVIG.
dc.identifier.doi10.4328/ACAM.22323
dc.identifier.endpage870
dc.identifier.issn2667-663X
dc.identifier.issue12
dc.identifier.startpage865
dc.identifier.urihttps://doi.org/10.4328/ACAM.22323
dc.identifier.urihttps://hdl.handle.net/11616/108378
dc.identifier.volume15
dc.identifier.wosWOS:001424161100011
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherBayrakol Medical Publisher
dc.relation.ispartofAnnals of Clinical and Analytical Medicine
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20250329
dc.subjectArds
dc.subjectCovid-19
dc.subjectCytokine Storm Syndrome
dc.subjectIvig
dc.subjectTocilizumab
dc.titleComparison of tocilizumab and intravenous immunoglobulin treatment in intensive care unit patients with COVID-19 who developed cytokine storm: A single-center retrospective study
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu